Literature DB >> 18455253

Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study.

Cesare Cozzarini1, Claudio Fiorino, Nadia Di Muzio, Riccardo Valdagni, Andrea Salonia, Filippo Alongi, Sara Broggi, Giorgio Guazzoni, Francesco Montorsi, Patrizio Rigatti, Riccardo Calandrino, Ferruccio Fazio.   

Abstract

PURPOSE: To report on planning and toxicity findings of hypofractionated adjuvant radiotherapy with helical Tomotherapy (HTT) after radical prostatectomy (RP) for prostate carcinoma (pCa). METHODS AND MATERIALS: Fifty consecutive patients submitted to RP for pT2R1/pT3a/pT3b-pN0 pCa were enrolled in a Phase I-II trial to receive 58Gy/20 fractions (5/week) on tumoral bed. Endpoint was to verify a risk of toxicity and biochemical failure not exceeding that observed in our Institutional 3DCRT, conventionally fractionated series (153 patients). Toxicities were graded according the RTOG scoring system.
RESULTS: Excellent coverage of PTV and high homogeneity of dose distribution were always achieved. Median follow-up was 25 months. Acute G2-3 RTOG genitourinary (GU) and acute G2 intestinal toxicities were similar (12% vs 15.6% and 4% vs 7%, respectively), while acute G2 proctitis was 0% vs 9% in HTT and 3DCRT group, respectively. Similarly, late Grade 2 gastrointestinal sequelae were 0% vs 8.5%. The incidence of late urethral stricture, 8% and 9% in HTT and 3DCRT group, respectively, is comparable to that of RP-only series.
CONCLUSIONS: Acute toxicity and early late toxicity outcomes of a moderately hypofractionated regimen with HTT post-RP are excellent. A longer follow-up is needed to fully assess the validity of this approach.

Entities:  

Mesh:

Year:  2008        PMID: 18455253     DOI: 10.1016/j.radonc.2008.03.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Volumetric image-guided highly conformal radiotherapy of the prostate bed: Toxicity analysis.

Authors:  Gianluca Ingrosso; Alessandra Carosi; Daniela di Cristino; Elisabetta Ponti; Andrea Lancia; Alessandra Murgia; Claudia Bruni; Pasquale Morelli; Franca Pietrasanta; Riccardo Santoni
Journal:  Rep Pract Oncol Radiother       Date:  2016-11-24

2.  The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?

Authors:  Giampiero Giovacchini; Andrea Ciarmiello; Elisabetta Giovannini; Andrei Fodor; Cesare Cozzarini; Paola Mapelli; Elena Incerti; Nadia Di Muzio; Luigi Gianolli; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-16       Impact factor: 9.236

Review 3.  Radiation-induced erectile dysfunction: Recent advances and future directions.

Authors:  Javed Mahmood; Aksinija A Shamah; T Michael Creed; Radmila Pavlovic; Hotaka Matsui; Masaki Kimura; Jason Molitoris; Hem Shukla; Isabel Jackson; Zeljko Vujaskovic
Journal:  Adv Radiat Oncol       Date:  2016-06-03

Review 4.  Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review.

Authors:  Christina Schröder; Hongjian Tang; Paul Windisch; Daniel Rudolf Zwahlen; André Buchali; Erwin Vu; Tilman Bostel; Tanja Sprave; Thomas Zilli; Vedang Murthy; Robert Förster
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

5.  Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.

Authors:  E Elif Ozkan; Alper Ozseven; Z Arda Kaymak Cerkesli
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

6.  Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial.

Authors:  Sonja Krause; Florian Sterzing; Dirk Neuhof; Lutz Edler; Juergen Debus; Klaus Herfarth
Journal:  BMC Cancer       Date:  2012-10-31       Impact factor: 4.430

Review 7.  Hypofractionated radiotherapy for prostate cancer.

Authors:  Nina-Sophie Hegemann; Matthias Guckenberger; Claus Belka; Ute Ganswindt; Farkhad Manapov; Minglun Li
Journal:  Radiat Oncol       Date:  2014-12-06       Impact factor: 3.481

Review 8.  Clinical utility of RapidArc™ radiotherapy technology.

Authors:  Erminia Infusino
Journal:  Cancer Manag Res       Date:  2015-11-12       Impact factor: 3.989

Review 9.  Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?

Authors:  Julia R Murray; Helen A McNair; David P Dearnaley
Journal:  Cancer Manag Res       Date:  2015-11-11       Impact factor: 3.989

10.  Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome.

Authors:  Salvina Barra; Liliana Belgioia; Michela Marcenaro; Serena Callegari; Alice Pastorino; Luca Trapani; Francesca Cavagnetto; Stefania Garelli; Renzo Corvò
Journal:  Cancer Manag Res       Date:  2018-03-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.